Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Gastrointestinal Endoscopy|June 28, 2011
Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancerManabu Muto, Hironaga Satake, Tomonori Yano, et al.
BMC Cancer|July 25, 2020
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancerMasaaki Miyo, Takeshi Kato, Takayuki Yoshino, et al.
Cancer Chemotherapy and Pharmacology|January 7, 2018
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)Hiroaki Yanagimoto, Hideyoshi Toyokawa, Daisuke Sakai, et al.
International Journal of Clinical Oncology|May 21, 2017
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)Koji Ando, Yasunori Emi, Toyokuni Suenaga, et al.
Anticancer Research|July 3, 2017
Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric CancerHironaga Satake, Masato Kondo, Motoko Mizumoto, et al.
Endoscopy|October 1, 2014
Clinical outcome after endoscopic resection for superficial pharyngeal squamous cell carcinoma invading the subepithelial layerHironaga Satake, Tomonori Yano, Manabu Muto, et al.
International Cancer Conference Journal|December 15, 2025
Resistance mechanism to pembrolizumab in DEK-AFF2 fusion-associated sinonasal squamous cell carcinomaShogen Boku, Takao Fujisawa, Shigenori Kadowaki, et al.
International Journal of Clinical Oncology|February 1, 2025
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancerKoji Ando, Hironaga Satake, Mototsugu Shimokawa, et al.
The Oncologist|May 12, 2021
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver MetastasesHironaga Satake, Hiroki Hashida, Hiroaki Tanioka, et al.
Clinical Medicine Insights. Oncology|November 21, 2022
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective StudyToshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, et al.
Pageof 12